MRTX - Bristol-Myers Squibb cut to Neutral at BofA despite recent M&A
2024-01-03 07:53:17 ET
More on Bristol-Myers Squibb
- Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
- Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management
- Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge
- Bristol Myers cancer therapy Augtyro under EU review
- What's in store for biotech M&A and IPOs in 2024?
For further details see:
Bristol-Myers Squibb cut to Neutral at BofA despite recent M&A